Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00205049|
Recruitment Status : Terminated (lack of funding)
First Posted : September 20, 2005
Results First Posted : May 13, 2014
Last Update Posted : May 13, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis, Alcoholic||Drug: pentoxifylline||Phase 1|
The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH.
This study never moved forward due to funding issues.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis|
|Study Start Date :||March 2005|
|Actual Primary Completion Date :||November 2006|
|Actual Study Completion Date :||November 2006|
All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
Other Name: no other names
- Survival at 28 Days [ Time Frame: 28 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00205049
|Principal Investigator:||Michael R Lucey, MD||University of Wisconsin, Madison|